SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

XIENCE™ Family of Drug Eluting Stents

The World's Leading Drug Eluting Stents (DES), with Unparalleled Clinical Outcomes1

XIENCE Family of Drug Eluting Stents

The XIENCE™ DES is proven to offer unparalleled patient outcomes during and long after percutaneous coronary interventions (PCI).1 With over 20 million implants and studied in 120+ clinical trials,* XIENCE™ Stent provides consistent long-term safety data out to 10 years.2 XIENCE™ Stent allows interventional cardiologists (ICs) to achieve the positive outcomes they want for their patients.

Carol's XIENCE story

1-month DAPT indication for
High Bleeding Risk Patients

Learn More

XIENCE Skypoint™ Drug Eluting Stent System

The newest DES in the XIENCE™ Family, XIENCE Skypoint™ Stent has an enhanced design that offers better expansion, excellent deliverability, a new 48 mm design, and trusted patient outcomes.1,4

View Product
Xience Skypoint

XIENCE Sierra™ Drug Eluting Stent System

XIENCE Sierra™ Stent has an enhanced design that offers deliverability, pushability, post dilatation expansion as well as an ultra-low profile and smoother crossing.†

View Product
Xience Sierra

 

* Data on file at Abbott. The 15 million implants is based on DES data through Q1 2020.

† Tests performed by and data on file at Abbott.

 

References

  1. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. • Serruys P, et al. N Engl J Med. 2010;363(2):136-146. • Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. • Kufner S, et al. Circulation. 2019:139(3):325-333. • Palmerini T, et al. Lancet. 2012;379(9824);1393-1402. • Bangalore S, et al. Circ Cardiovasc Interv. 2013;6:378-390. • Pilgrim T, et al. Lancet. 2014;384:2111-2122. • Pilgrim T, et al. Lancet 2018;392:737-746.
  2. Kufner S, et al. Circulation. 2019:139(3):325-333. Shiomi H, et al. J Am Coll Cardiol Interv. 2019;12:637-647. Data on file at Abbott.
  3. Data on file at Abbott – 12 million patients number is based on data of DES implants through Q2, 2022. Outcomes may not be representative of all patients. See – Kufner S, et al. Circulation. 2019;139:325-333 – for XIENCE™ Stent long term clinical outcomes.
  4. XIENCE Skypoint™ Stent Instructions for use. Tests performed and data on file at Abbott - 3.0 x 18 mm stents tested using a simulated arterial model. Data on file at Abbott.

MAT-2006547 v5.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2024 Abbott. All Rights Reserved.

MAT-2001111 v7.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

YES

MAT-2305078 v1.0